Duloxetine Sprinkle Dosage Form Acid Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Duloxetine, an acid-labile drug, degrades in acidic environments, leading to toxic side effects and stability issues in gastrointestinal tract, making existing delayed release formulations unsuitable for patients with swallowing difficulties or enteral feeding tubes, requiring a formulation with higher acid resistance and improved bioavailability.
Innovation Solution
A multiparticulate sprinkle dosage form comprising enteric-coated discrete units of duloxetine hydrochloride, coated with an enteric polymer like hydroxypropylmethyl cellulose phthalate, which maintains stability and bioequivalence to existing delayed release capsules, allowing administration via nasogastric tube or enteral feeding tube and soft food without affecting the enteric coating.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enteric coated capsules are used to protect duloxetine from acid degradation, then acid resistance is improved, but patient compliance deteriorates due to swallowing difficulties
Solution Approach 1:
The invention divides the conventional capsule into multiple smaller discrete units (sprinkles) that can be easily administered. Each sprinkle contains enteric-coated duloxetine pellets, maintaining acid protection while eliminating swallowing difficulties. The segmented form allows the medication to be sprinkled on food or administered via feeding tubes, directly resolving the contradiction between acid resistance and patient compliance.
Solution Approach 2:
The invention nests enteric-coated duloxetine pellets within a sprinkle carrier structure. The pellets are embedded in an inert matrix material that provides structural integrity while allowing the active ingredient to remain protected. This nested configuration maintains the acid-resistant properties of the enteric coating while enabling easy administration through alternative routes.
2Ease of operation
If liquid or chewable dosage forms are used to improve administration ease, then patient compliance is improved, but acid resistance deteriorates leading to drug degradation
Solution Approach 1:
The invention introduces an enteric coating as an intermediary layer between the acid-labile duloxetine and the gastric acid environment. This coating acts as a protective mediator that prevents direct contact between the drug and acid, allowing the medication to be administered in easily consumable forms (sprinkles on food, via feeding tubes) without compromising acid resistance. The intermediary coating resolves the contradiction by decoupling administration ease from acid protection requirements.
3Adaptability or versatility
If prolonged gastric residence time occurs in diabetic patients, then administration flexibility is improved, but drug stability deteriorates due to extended acid exposure
Solution Approach 1:
The invention applies enteric coating to the duloxetine pellets before administration, performing the protective action in advance. This preliminary coating ensures that the drug is protected from acid degradation before it encounters the gastric environment, regardless of how long it remains there. The pre-applied protective layer allows flexible administration timing while maintaining drug stability during extended gastric residence.
Solution Approach 2:
The invention uses a disposable enteric coating layer that sacrifices itself to protect the drug during gastric transit. This single-use protective barrier provides sufficient protection during the brief gastric residence period and then allows drug release in the intestine, accommodating variable gastric emptying times in diabetic patients while maintaining drug stability.
4Stability of the object's composition
If conventional enteric coated formulations are used to prevent acid degradation, then drug stability is improved, but bioavailability deteriorates due to alcohol-induced dose dumping
Solution Approach 1:
The invention uses a composite structure consisting of enteric-coated pellets embedded in an inert matrix material. The enteric coating provides acid resistance while the matrix material provides structural integrity and controlled release properties. This composite configuration maintains drug stability in acid while preventing alcohol-induced dose dumping, as the matrix structure prevents premature release even when the enteric coating is exposed to alcohol in the intestine.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multiparticulate sprinkle dosage form exhibits higher acid resistance, maintaining stability and bioequivalence, with reduced 1-naphthol impurity release and enhanced bioavailability, suitable for patients with swallowing difficulties and enteral feeding tubes, and resistant to alcohol-induced dose dumping.
Implementation Method 1
Duloxetine is an acid labile drug and degrades in acidic environment of gastrointestinal tract (GIT). Acid hydrolysis of its ether linkage results in the formation of 1-naphthol
Implementation Method 2
at pH 1.0, which is achieved under fasting conditions in vivo, 50% of drug in the dosage is hydrolyzed to 1-naphthol; at pH of 2.0, 10% of the drug degrades to 1-naphthol in one hour, and at a pH of 4.0, 10% degradation would take up to 63 hours
Data Source
AI summary
The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.